Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2022 | Aug. 10, 2022 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001053691 | |
Entity Registrant Name | Diffusion Pharmaceuticals Inc. | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2022 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2022 | |
Document Transition Report | false | |
Entity File Number | 000-24477 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 30-0645032 | |
Entity Address, Address Line One | 300 East Main Street, Suite 201 | |
Entity Address, City or Town | Charlottesville | |
Entity Address, State or Province | VA | |
Entity Address, Postal Zip Code | 22902 | |
City Area Code | 434 | |
Local Phone Number | 220-0718 | |
Title of 12(b) Security | Common Stock, par value $0.001 per share | |
Trading Symbol | DFFN | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 2,039,120 |
Consolidated Balance Sheets (Cu
Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 5,965,726 | $ 37,313,558 |
Marketable securities | 22,574,681 | 0 |
Prepaid expenses, deposits and other current assets | 643,618 | 510,015 |
Total current assets | 29,184,025 | 37,823,573 |
Other assets | 0 | 15,578 |
Total assets | 29,184,025 | 37,839,151 |
Current liabilities: | ||
Accounts payable | 846,032 | 947,495 |
Accrued expenses and other current liabilities | 1,668,990 | 1,980,189 |
Total current liabilities | 2,515,022 | 2,927,684 |
Commitments and Contingencies (Note 9) | ||
Stockholders’ Equity: | ||
Common stock, $0.001 par value: 1,000,000,000 shares authorized: 2,038,914 and 2,038,185 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively | 2,038 | 2,038 |
Additional paid-in capital | 165,475,801 | 164,914,540 |
Accumulated other comprehensive loss | (86,583) | 0 |
Accumulated deficit | (138,722,253) | (130,005,111) |
Total stockholders' equity | 26,669,003 | 34,911,467 |
Total liabilities and stockholders' equity | $ 29,184,025 | $ 37,839,151 |
Consolidated Balance Sheets (_2
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Jun. 30, 2022 | Dec. 31, 2021 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 1,000,000,000 | 1,000,000,000 |
Common stock, shares issued (in shares) | 2,038,914 | 2,038,185 |
Common stock, shares outstanding (in shares) | 2,038,914 | 2,038,185 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Operating expenses: | ||||
Research and development | $ 2,108,553 | $ 1,972,673 | $ 4,534,451 | $ 4,889,051 |
General and administrative | 2,137,326 | 1,836,773 | 4,265,878 | 3,580,283 |
Depreciation | 0 | 23,755 | 0 | 48,202 |
Loss from operations | 4,245,879 | 3,833,201 | 8,800,329 | 8,517,536 |
Interest income | (55,378) | (55,228) | (83,187) | (95,644) |
Net loss | $ (4,190,501) | $ (3,777,973) | $ (8,717,142) | $ (8,421,892) |
Per share information: | ||||
Net loss per share of common stock, basic and diluted (in dollars per share) | $ (2.06) | $ (1.85) | $ (4.28) | $ (4.54) |
Weighted average shares outstanding, basic and diluted (in shares) | 2,038,727 | 2,037,978 | 2,038,529 | 1,854,161 |
Comprehensive loss: | ||||
Net loss | $ (4,190,501) | $ (3,777,973) | $ (8,717,142) | $ (8,421,892) |
Unrealized loss on marketable securities | (36,925) | 0 | (86,583) | 0 |
Comprehensive loss: | $ (4,227,426) | $ (3,777,973) | $ (8,803,725) | $ (8,421,892) |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) | Total | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] |
Balance (in shares) at Dec. 31, 2020 | 1,280,207 | |||||
Unrealized loss on marketable securities | $ 0 | |||||
Net loss | (8,421,892) | $ 0 | $ 0 | $ (8,421,892) | ||
Balance (in shares) at Jun. 30, 2021 | 2,037,978 | |||||
Balance at Dec. 31, 2020 | 24,814,182 | $ 1,280 | 130,722,286 | (105,909,384) | ||
Sale of common stock and warrants, net of issuance costs (in shares) | 673,171 | |||||
Sale of common stock and warrants, net of issuance costs | 31,094,302 | $ 673 | 31,093,629 | 0 | ||
Issuance of common stock upon exercise of warrants (in shares) | 84,600 | |||||
Issuance of common stock upon exercise of warrants | 2,201,450 | $ 85 | 2,201,365 | 0 | ||
Stock-based compensation expense | 478,560 | 0 | 478,560 | 0 | ||
Balance at Jun. 30, 2021 | 50,166,602 | $ 2,038 | 164,495,840 | (114,331,276) | ||
Balance (in shares) at Mar. 31, 2021 | 2,037,978 | |||||
Unrealized loss on marketable securities | 0 | |||||
Net loss | (3,777,973) | $ 0 | 0 | (3,777,973) | ||
Balance (in shares) at Jun. 30, 2021 | 2,037,978 | |||||
Balance at Mar. 31, 2021 | 53,647,295 | $ 2,038 | 164,198,560 | (110,553,303) | ||
Sale of common stock and warrants, net of issuance costs (in shares) | 0 | |||||
Sale of common stock and warrants, net of issuance costs | 0 | $ 0 | 0 | 0 | ||
Issuance of common stock upon exercise of warrants (in shares) | 0 | |||||
Issuance of common stock upon exercise of warrants | 0 | $ 0 | 0 | 0 | ||
Stock-based compensation expense | 297,280 | 0 | 297,280 | 0 | ||
Balance at Jun. 30, 2021 | 50,166,602 | $ 2,038 | 164,495,840 | (114,331,276) | ||
Balance (in shares) at Dec. 31, 2021 | 0 | 2,038,185 | ||||
Balance at Dec. 31, 2021 | 34,911,467 | $ 0 | $ 2,038 | 164,914,540 | $ 0 | (130,005,111) |
Conversion of Series C preferred stock to common stock (in shares) | (10,000) | |||||
Conversion of Series C preferred stock to common stock | $ (5,000) | |||||
Conversion of Series C preferred stock to common stock (in shares) | 200 | |||||
Stock-based compensation expense and vesting of restricted stock units (in shares) | 0 | 529 | ||||
Stock-based compensation expense and vesting of restricted stock units | 556,261 | $ 0 | $ 0 | 556,261 | 0 | 0 |
Unrealized loss on marketable securities | (86,583) | 0 | 0 | 0 | (86,583) | 0 |
Net loss | (8,717,142) | $ 0 | $ 0 | 0 | 0 | (8,717,142) |
Balance (in shares) at Jun. 30, 2022 | 0 | 2,038,914 | ||||
Balance at Jun. 30, 2022 | 26,669,003 | $ 0 | $ 2,038 | 165,475,801 | (86,583) | (138,722,253) |
Sale of Series C preferred stock to related parties (in shares) | 10,000 | 0 | ||||
Sale of Series C preferred stock to related parties | 5,000 | $ 5,000 | $ 0 | 0 | 0 | 0 |
Balance (in shares) at Mar. 31, 2022 | 10,000 | 2,038,392 | ||||
Balance at Mar. 31, 2022 | 30,618,299 | $ 5,000 | $ 2,038 | 165,192,671 | (49,658) | (134,531,752) |
Conversion of Series C preferred stock to common stock (in shares) | (10,000) | |||||
Conversion of Series C preferred stock to common stock | $ (5,000) | |||||
Conversion of Series C preferred stock to common stock (in shares) | 200 | |||||
Stock-based compensation expense and vesting of restricted stock units (in shares) | 0 | 322 | ||||
Stock-based compensation expense and vesting of restricted stock units | 278,130 | $ 0 | $ 0 | 278,130 | 0 | 0 |
Unrealized loss on marketable securities | (36,925) | 0 | 0 | 0 | (36,925) | 0 |
Net loss | (4,190,501) | $ 0 | $ 0 | 0 | 0 | (4,190,501) |
Balance (in shares) at Jun. 30, 2022 | 0 | 2,038,914 | ||||
Balance at Jun. 30, 2022 | $ 26,669,003 | $ 0 | $ 2,038 | 165,475,801 | $ (86,583) | $ (138,722,253) |
Conversion of Series C preferred stock to common stock | $ 5,000 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Operating activities: | ||
Net loss | $ (8,717,142) | $ (8,421,892) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation | 0 | 48,202 |
Stock-based compensation expense | 556,261 | 478,560 |
Amortization of premium and discount on marketable securities | (45,439) | 0 |
Changes in operating assets and liabilities: | ||
Prepaid expenses, deposits and other assets | (118,025) | (291,068) |
Accounts payable, accrued expenses and other liabilities | (412,662) | (317,576) |
Net cash used in operating activities | (8,737,007) | (8,503,774) |
Cash flows provided by investing activities: | ||
Purchase of marketable securities | (31,615,825) | 0 |
Maturities of marketable securities | 9,000,000 | 0 |
Net cash used in investing activities | (22,615,825) | 0 |
Proceeds from the sale of preferred stock | 5,000 | 0 |
Proceeds from the exercise of common stock warrants | 0 | 2,201,450 |
Proceeds from the sale of common stock | 0 | 31,094,302 |
Net cash provided by financing activities | 5,000 | 33,295,752 |
Net (decrease) increase in cash and cash equivalents | (31,347,832) | 24,791,978 |
Cash and cash equivalents at beginning of period | 37,313,558 | 18,515,595 |
Cash and cash equivalents at end of period | 5,965,726 | 43,307,573 |
Supplemental disclosure of non-cash activities: | ||
Unrealized loss on marketable securities | $ 86,583 | $ 0 |
Note 1 - Organization and Descr
Note 1 - Organization and Description of Business | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. Organization and Description of Business Diffusion Pharmaceuticals Inc., a Delaware corporation, is a biopharmaceutical company developing novel therapies to enhance the body’s ability to deliver oxygen to areas where it is needed most. The Company’s lead product candidate, TSC, is being investigated to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions, including hypoxic solid tumors. On April 18, 2022, 1 |
Note 2 - Liquidity
Note 2 - Liquidity | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Liquidity Disclosure [Text Block] | 2. Liquidity The Company has not No The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third not may third may not In July 2022, "2022 may 415 4 1933, Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company’s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company’s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company’s financial condition and future operations. The Company currently expects that its existing cash, cash equivalents and marketable securities as of June 30, 2022 first 2024, may |
Note 3 - Basis of Presentation
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 3. Basis of Presentation and Summary of Significant Accounting Policies The Summary of Significant Accounting Policies included in the Company's Annual Report for the year ended December 31, 2021 not Basis of Presentation The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information as found in the ASC and ASUs of the FASB, and with the instructions to Form 10 10 X June 30, 2022, three six June 30, 2022 2021 six June 30, 2022 2021. six June 30, 2022 not may December 31, 2022. not December 31, 2021 Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates. Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments. Concentration of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits. Cash and Cash Equivalents The Company considers any highly-liquid investments, such as money market funds and commercial paper with an original maturity of three Marketable Securities The Company classifies its marketable securities as available-for-sale, which include commercial paper and U.S. government debt securities with original maturities of greater than three Reverse Stock Split On April 18, 2022, 1 one five 2015 Net Loss Per Common Share Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not The following potentially dilutive securities outstanding as of June 30, 2022 2021 As of June 30, 2022 2021 Common stock warrants 111,891 129,989 Stock options 122,882 61,058 Unvested restricted stock awards 4,672 3,060 239,445 194,107 Recently Issued Accounting Pronouncements In June 2016, 2016 13, Financial Instruments Credit Losses, Measurement of Credit Losses on Financial Instruments 326 no January 1, 2023. not |
Note 4 - Cash, Cash Equivalents
Note 4 - Cash, Cash Equivalents and Marketable Securities | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Cash, Cash Equivalents, and Marketable Securities [Text Block] | 4. Cash, cash equivalents and marketable securities The following is a summary of the Company's cash and cash equivalents as of the dates indicated: June 30, 2022 December 31, 2021 Cash in banking institutions $ 1,084,595 $ 30,308,075 Money market funds 3,886,704 7,005,483 Commercial paper 994,427 — Total $ 5,965,726 $ 37,313,558 The following is a summary of the Company's marketable securities as of June 30, 2022: Amortized cost Unrealized gains Unrealized losses Fair Value Commercial paper $ 17,658,057 $ 25 $ (57,001 ) $ 17,601,081 U.S. treasury bonds 5,003,207 — (29,607 ) 4,973,600 Total $ 22,661,264 $ 25 $ (86,608 ) $ 22,574,681 The Company did not December 31, 2021. June 30, 2022. June 30, 2022 not not six June 30, 2022 six June 30, 2021. |
Note 5 - Fair Value of Financia
Note 5 - Fair Value of Financial Instruments | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 5. Fair Value of Financial Instruments Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company’s financial instruments, including prepaid expense and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, Fair Value Measurement one three • Level 1: • Level 2: not • Level 3: no The following table presents the Company’s assets that are measured at fair value on a recurring basis (amounts in thousands): Fair value measurement at reporting date Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) June 30, 2022: Cash equivalents: Money market funds $ 3,886,704 $ — $ — Commercial paper — 994,427 — Total cash equivalents $ 3,886,704 $ 994,427 $ — Marketable securities Commercial paper $ — $ 17,601,081 $ — US treasury — 4,973,600 — Total marketable securities $ — $ 22,574,681 $ — Total financial assets $ 3,886,704 $ 23,569,108 $ — The fair values of the Company’s Level 2 two may |
Note 6 - Accrued Expenses and O
Note 6 - Accrued Expenses and Other Current Liabilities | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] | 6. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following as of the dates indicated below: June 30, 2022 December 31, 2021 Accrued payroll and payroll related expenses $ 661,061 $ 879,971 Accrued professional fees 163,269 247,704 Accrued clinical studies expenses 766,916 786,579 Other accrued expenses 77,744 65,935 Total $ 1,668,990 $ 1,980,189 |
Note 7 - Stockholders' Equity a
Note 7 - Stockholders' Equity and Common Stock Warrants | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 7. Stockholders' Equity and Common Stock Warrants Private Placement of Series C Preferred Stock On March 18, 2022, 100% $5,000. The Series C Certificate provides that, among other things, (i) each share of Series C Preferred Stock is convertible into 0.02 shares of the Company's common stock, representing a conversion price of $25.00 per share, subject to certain conditions, (ii) each share of Series C Preferred Stock outstanding is counted on an as converted basis, together with the Company’s common stock as a single class, for purposes of determining the presence of a quorum at any meeting at which holders are asked to vote on matters related to the Reverse Stock Split (subject to any applicable exchange listing rules), (iii) each share of Series C Preferred Stock outstanding has the right to cast 1,600 not On April 18, 2022, Common Stock Warrants During its evaluation of equity classification for the Company's common stock warrants issued in previous periods, the Company considered the conditions as prescribed within ASC 815 40, Derivatives and Hedging, Contracts in an Entity s own Equity 815 40 not not 480 Distinguishing Liabilities from Equity not not 815, As of June 30, 2022, Outstanding Range of exercise price per share Expiration dates Common stock warrants issued in 2018 related to the January 2018 Offering 23,639 599.711749.7676 January 2023 Common stock warrants issued related to the May 2019 Offering 27,648 250.099306.0404 May and December 2024 Common stock warrants issued related to the November 2019 Offering 4,269 $17.51 November 2024 Common stock warrants issued related to the December 2019 Offering 6,264 21.68834.9292 December 2024 and June 2025 Common stock warrants issued related to the May 2020 Offering 11,424 $65.65 March 2025 Common stock warrants issued related to May 2020 Investor Warrant Exercise 4,998 $29.7 November 2025 Common stock warrants issued related to the February 2021 Offering 33,649 $64.08 February 2026 111,891 During the six June 30, 2022, |
Note 8 - Stock-based Compensati
Note 8 - Stock-based Compensation | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Share-Based Payment Arrangement [Text Block] | 8. Stock-Based Compensation 2015 The 2015 January 1 December 31, January 1, 2022, may 2015 June 30, 2022, 2015 The Company recorded stock-based compensation expense in the following expense categories of its unaudited interim consolidated statements of operations for the periods indicated: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 58,892 $ 59,567 $ 117,785 $ 92,567 General and administrative 219,238 237,713 438,476 385,993 Total stock-based compensation expense $ 278,130 $ 297,280 $ 556,261 $ 478,560 The following table summarizes the activity related to all stock option grants for the six June 30, 2022: Number of Options Weighted average exercise price per share Weighted average remaining contractual life (in years) Aggregate intrinsic value Balance at January 1, 2021 72,454 $ 265.85 Granted 56,300 11.40 Forfeited (5,612 ) 188.18 Expired (260 ) 1,575 Outstanding at June 30, 2022 122,882 $ 149.96 8.8 $ — Exercisable at June 30, 2022 60,688 $ 283.73 8.1 $ — Vested and expected to vest at June 30, 2022 122,882 $ 149.96 8.8 $ — The weighted average grant date fair value of stock option awards granted during the six June 30, 2022 three June 30, 2022 2021 six June 30, 2022 2021 June 30, 2022, Options granted were valued using the Black-Scholes option-pricing model and the weighted average assumptions used to value the options granted during the six June 30, 2022 2021 2022 2021 Expected term (in years) 5.74 10 Risk-free interest rate 1.9 % 1.5 % Expected volatility 135.0 % 124.5 % Dividend yield — % — % Restricted Stock Unit Awards The Company issues restricted stock units ("RSU") to newly elected, non-executive members of the board of directors that vest in six, tri-monthly installments beginning 18 months after the respective grant date. The fair value of a RSU is equal to the fair market value price of the Company’s common stock on the date of grant. RSU expense is recorded on a straight-line basis over the service period. The following table summarizes activity related to RSU awards during the period indicated: Number of Units Weighted average grant date fair value Balance at January 1, 2022 5,509 $ 34.78 Vested (1) (837 ) 29.87 Outstanding at June 30, 2022 4,672 $ 35.66 ( 1 six June 30, 2022 The Company recognized approximately $16,000 and $5,000 in expense related to these awards during the three June 30, 2022 2021, six June 30, 2022 2021, June 30, 2022, |
Note 9 - Commitments and Contin
Note 9 - Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 9. Commitments and Contingencies Office Space Lease Commitment The Company has short term agreements to utilize membership-based co-working space in both Charlottesville, Virginia and Philadelphia, Pennsylvania. Rent expense related to the Company's short-term agreements for the three June 30, 2022 2021 six June 30, 2022 2021, Research and Development Arrangements In the course of normal business operations, the Company enters into agreements with universities and CROs to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to CROs represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may Defined Contribution Retirement Plan The Company has established its 401 may 401 401 three 401 six June 30, 2022 2021, Legal Proceedings On August 7, 2014, No. BC553996 December 30, 2014, April 1, 2015, April 14, 2015, January 8, 2016, November 19, 2018 not November 2020 19 November 2018 October 22, 2021, not February 23, 2022 May 24, 2023 The Company believes the claims in this matter are without merit and intends to defend itself vigorously. However, at this stage, the Company is unable to predict the outcome and possible loss or range of loss, if any, associated with its resolution or any potential effect the matter may |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information as found in the ASC and ASUs of the FASB, and with the instructions to Form 10 10 X June 30, 2022, three six June 30, 2022 2021 six June 30, 2022 2021. six June 30, 2022 not may December 31, 2022. not December 31, 2021 |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates. |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments. |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers any highly-liquid investments, such as money market funds and commercial paper with an original maturity of three |
Marketable Securities, Policy [Policy Text Block] | Marketable Securities The Company classifies its marketable securities as available-for-sale, which include commercial paper and U.S. government debt securities with original maturities of greater than three |
Stockholders' Equity, Policy [Policy Text Block] | Reverse Stock Split On April 18, 2022, 1 one five 2015 |
Earnings Per Share, Policy [Policy Text Block] | Net Loss Per Common Share Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not The following potentially dilutive securities outstanding as of June 30, 2022 2021 As of June 30, 2022 2021 Common stock warrants 111,891 129,989 Stock options 122,882 61,058 Unvested restricted stock awards 4,672 3,060 239,445 194,107 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Issued Accounting Pronouncements In June 2016, 2016 13, Financial Instruments Credit Losses, Measurement of Credit Losses on Financial Instruments 326 no January 1, 2023. not |
Note 3 - Basis of Presentatio_2
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | As of June 30, 2022 2021 Common stock warrants 111,891 129,989 Stock options 122,882 61,058 Unvested restricted stock awards 4,672 3,060 239,445 194,107 |
Note 4 - Cash, Cash Equivalen_2
Note 4 - Cash, Cash Equivalents and Marketable Securities (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Schedule of Cash and Cash Equivalents [Table Text Block] | June 30, 2022 December 31, 2021 Cash in banking institutions $ 1,084,595 $ 30,308,075 Money market funds 3,886,704 7,005,483 Commercial paper 994,427 — Total $ 5,965,726 $ 37,313,558 |
Debt Securities, Available-for-Sale [Table Text Block] | Amortized cost Unrealized gains Unrealized losses Fair Value Commercial paper $ 17,658,057 $ 25 $ (57,001 ) $ 17,601,081 U.S. treasury bonds 5,003,207 — (29,607 ) 4,973,600 Total $ 22,661,264 $ 25 $ (86,608 ) $ 22,574,681 |
Note 5 - Fair Value of Financ_2
Note 5 - Fair Value of Financial Instruments (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Fair Value, Assets Measured on Recurring Basis [Table Text Block] | Fair value measurement at reporting date Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) June 30, 2022: Cash equivalents: Money market funds $ 3,886,704 $ — $ — Commercial paper — 994,427 — Total cash equivalents $ 3,886,704 $ 994,427 $ — Marketable securities Commercial paper $ — $ 17,601,081 $ — US treasury — 4,973,600 — Total marketable securities $ — $ 22,574,681 $ — Total financial assets $ 3,886,704 $ 23,569,108 $ — |
Note 6 - Accrued Expenses and_2
Note 6 - Accrued Expenses and Other Current Liabilities (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Other Current Liabilities [Table Text Block] | June 30, 2022 December 31, 2021 Accrued payroll and payroll related expenses $ 661,061 $ 879,971 Accrued professional fees 163,269 247,704 Accrued clinical studies expenses 766,916 786,579 Other accrued expenses 77,744 65,935 Total $ 1,668,990 $ 1,980,189 |
Note 7 - Stockholders' Equity_2
Note 7 - Stockholders' Equity and Common Stock Warrants (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Outstanding Range of exercise price per share Expiration dates Common stock warrants issued in 2018 related to the January 2018 Offering 23,639 599.711749.7676 January 2023 Common stock warrants issued related to the May 2019 Offering 27,648 250.099306.0404 May and December 2024 Common stock warrants issued related to the November 2019 Offering 4,269 $17.51 November 2024 Common stock warrants issued related to the December 2019 Offering 6,264 21.68834.9292 December 2024 and June 2025 Common stock warrants issued related to the May 2020 Offering 11,424 $65.65 March 2025 Common stock warrants issued related to May 2020 Investor Warrant Exercise 4,998 $29.7 November 2025 Common stock warrants issued related to the February 2021 Offering 33,649 $64.08 February 2026 111,891 |
Note 8 - Stock-based Compensa_2
Note 8 - Stock-based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 58,892 $ 59,567 $ 117,785 $ 92,567 General and administrative 219,238 237,713 438,476 385,993 Total stock-based compensation expense $ 278,130 $ 297,280 $ 556,261 $ 478,560 |
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | Number of Options Weighted average exercise price per share Weighted average remaining contractual life (in years) Aggregate intrinsic value Balance at January 1, 2021 72,454 $ 265.85 Granted 56,300 11.40 Forfeited (5,612 ) 188.18 Expired (260 ) 1,575 Outstanding at June 30, 2022 122,882 $ 149.96 8.8 $ — Exercisable at June 30, 2022 60,688 $ 283.73 8.1 $ — Vested and expected to vest at June 30, 2022 122,882 $ 149.96 8.8 $ — |
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | 2022 2021 Expected term (in years) 5.74 10 Risk-free interest rate 1.9 % 1.5 % Expected volatility 135.0 % 124.5 % Dividend yield — % — % |
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] | Number of Units Weighted average grant date fair value Balance at January 1, 2022 5,509 $ 34.78 Vested (1) (837 ) 29.87 Outstanding at June 30, 2022 4,672 $ 35.66 |
Note 1 - Organization and Des_2
Note 1 - Organization and Description of Business (Details Textual) | Apr. 18, 2022 |
Reverse Stock Split [Member ] | |
Stockholders' Equity Note, Stock Split, Conversion Ratio | 50 |
Note 2 - Liquidity (Details Tex
Note 2 - Liquidity (Details Textual) $ in Millions | Jun. 30, 2022 USD ($) |
BTIG, LLC [Member] | |
Common Stock, Value, Subscriptions | $ 20 |
Note 3 - Basis of Presentatio_3
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) shares in Thousands | Apr. 18, 2022 $ / shares shares |
Stock Issued During Period, Fractional Shares, Reverse Stock Split (in shares) | shares | 0 |
Reverse Stock Split, Fractional Shares, Cash, Multiple (in dollars per share) | $ / shares | $ 12.93 |
Reverse Stock Split [Member ] | |
Stockholders' Equity Note, Stock Split, Conversion Ratio | 50 |
Note 3 - Basis of Presentatio_4
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details) - shares | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Anti-dilutive securities (in shares) | 239,445 | 194,107 |
Warrant [Member] | ||
Anti-dilutive securities (in shares) | 111,891 | 129,989 |
Share-Based Payment Arrangement, Option [Member] | ||
Anti-dilutive securities (in shares) | 122,882 | 61,058 |
Restricted Stock [Member] | ||
Anti-dilutive securities (in shares) | 4,672 | 3,060 |
Note 4 - Cash, Cash Equivalen_3
Note 4 - Cash, Cash Equivalents and Marketable Securities (Details Textual) - USD ($) | 6 Months Ended | |
Jun. 30, 2022 | Dec. 31, 2021 | |
Debt Securities, Available-for-Sale, Total | $ 22,574,681 | $ 0 |
Marketable Securities, Other-than-temporary Impairment Loss | 0 | |
Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss | $ 0 | |
Minimum [Member] | ||
Marketable Securities Contractual Maturity (Month) | 3 months | |
Maximum [Member] | ||
Marketable Securities Contractual Maturity (Month) | 12 months |
Note 4 - Cash, Cash Equivalen_4
Note 4 - Cash, Cash Equivalents and Marketable Securities - Cash and Cah Equivalents (Details) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Cash and cash equivalents | $ 5,965,726 | $ 37,313,558 |
Bank Time Deposits [Member] | ||
Cash and cash equivalents | 1,084,595 | 30,308,075 |
Money Market Funds [Member] | ||
Cash and cash equivalents | 3,886,704 | 7,005,483 |
Commercial Paper [Member] | ||
Cash and cash equivalents | $ 994,427 | $ 0 |
Note 4 - Cash, Cash Equivalen_5
Note 4 - Cash, Cash Equivalents and Marketable Securities - Marketable Securities (Details) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Amortized cost | $ 22,661,264 | |
Commercial paper | 25 | |
Commercial paper | (86,608) | |
Fair Value | 22,574,681 | $ 0 |
Commercial Paper, Not Included with Cash and Cash Equivalents [Member] | ||
Amortized cost | 17,658,057 | |
Commercial paper | 25 | |
Commercial paper | (57,001) | |
Fair Value | 17,601,081 | |
US Treasury Securities [Member] | ||
Amortized cost | 5,003,207 | |
Commercial paper | 0 | |
Commercial paper | (29,607) | |
Fair Value | $ 4,973,600 |
Note 5 - Fair Value of Financ_3
Note 5 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Fair Value | $ 22,574,681 | $ 0 |
Commercial Paper, Not Included with Cash and Cash Equivalents [Member] | ||
Fair Value | 17,601,081 | |
US Treasury Securities [Member] | ||
Fair Value | 4,973,600 | |
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | ||
Cash and cash equivalents | 3,886,704 | |
Fair Value | 0 | |
Total financial assets | 3,886,704 | |
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member] | ||
Fair Value | 0 | |
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | US Treasury Securities [Member] | ||
Fair Value | 0 | |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | ||
Cash and cash equivalents | 994,427 | |
Fair Value | 22,574,681 | |
Total financial assets | 23,569,108 | |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member] | ||
Fair Value | 17,601,081 | |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | US Treasury Securities [Member] | ||
Fair Value | 4,973,600 | |
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | ||
Cash and cash equivalents | 0 | |
Fair Value | 0 | |
Total financial assets | 0 | |
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member] | ||
Fair Value | 0 | |
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | US Treasury Securities [Member] | ||
Fair Value | 0 | |
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | ||
Cash and cash equivalents | 3,886,704 | |
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | ||
Cash and cash equivalents | 0 | |
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | ||
Cash and cash equivalents | 0 | |
Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | ||
Cash and cash equivalents | 0 | |
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | ||
Cash and cash equivalents | 994,427 | |
Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | ||
Cash and cash equivalents | $ 0 |
Note 6 - Accrued Expenses and_3
Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Accrued payroll and payroll related expenses | $ 661,061 | $ 879,971 |
Accrued professional fees | 163,269 | 247,704 |
Accrued clinical studies expenses | 766,916 | 786,579 |
Other accrued expenses | 77,744 | 65,935 |
Total | $ 1,668,990 | $ 1,980,189 |
Note 7 - Stockholders' Equity_3
Note 7 - Stockholders' Equity and Common Stock Warrants (Details Textual) | 6 Months Ended | ||
Apr. 18, 2022 shares | Mar. 18, 2022 USD ($) $ / shares shares | Jun. 30, 2022 shares | |
Class of Warrant or Rights, Expired (in shares) | 18,077 | ||
Conversion of Series C Preferred Stock into Common Stock [Member] | |||
Conversion of Stock, Shares Converted (in shares) | 10,000 | ||
Conversion of Stock, Shares Issued (in shares) | 200 | ||
Series C Preferred Stock [Member] | |||
Preferred Stock, Convertible, Conversion Ratio | 0.02 | ||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 25 | ||
Series C Preferred Stock [Member] | President [Member] | |||
Stock Issued During Period, Shares, New Issues (in shares) | 10,000 | ||
Sale of Stock, Price Per Share (in dollars per share) | $ / shares | $ 0.50 | ||
Proceeds from Issuance of Convertible Preferred Stock | $ | $ 5,000 |
Note 7 - Stockholders' Equity_4
Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details) | Jun. 30, 2022 $ / shares shares |
Common stock warrants, outstanding (in shares) | shares | 111,891 |
Warrants Issued in Connection with the January 2018 Offering [Member] | |
Common stock warrants, outstanding (in shares) | shares | 23,639 |
Warrants Issued in Connection with the January 2018 Offering [Member] | Minimum [Member] | |
Range of exercise price (in dollars per share) | $ 599.71 |
Warrants Issued in Connection with the January 2018 Offering [Member] | Maximum [Member] | |
Range of exercise price (in dollars per share) | $ 749.76 |
Warrants Issued in Connection with May 2019 Public Offering [Member] | |
Common stock warrants, outstanding (in shares) | shares | 27,648 |
Warrants Issued in Connection with May 2019 Public Offering [Member] | Minimum [Member] | |
Range of exercise price (in dollars per share) | $ 250.09 |
Warrants Issued in Connection with May 2019 Public Offering [Member] | Maximum [Member] | |
Range of exercise price (in dollars per share) | $ 306.04 |
Warrants Issued in Connection with the November 2019 Offering [Member] | |
Common stock warrants, outstanding (in shares) | shares | 4,269 |
Range of exercise price (in dollars per share) | $ 17.51 |
Warrants Issued in Connection with the December 2019 Offering [Member] | |
Common stock warrants, outstanding (in shares) | shares | 6,264 |
Warrants Issued in Connection with the December 2019 Offering [Member] | Minimum [Member] | |
Range of exercise price (in dollars per share) | $ 21.68 |
Warrants Issued in Connection with the December 2019 Offering [Member] | Maximum [Member] | |
Range of exercise price (in dollars per share) | $ 34.92 |
Common Stock Warrants Issued Related to May 2020 Common Stock Offering [Member] | |
Common stock warrants, outstanding (in shares) | shares | 11,424 |
Range of exercise price (in dollars per share) | $ 65.65 |
The May 2020 Investor Warrant Exercise [Member] | |
Common stock warrants, outstanding (in shares) | shares | 4,998 |
Range of exercise price (in dollars per share) | $ 29.7 |
Common Stock Warrants Issued Related to February 2021 Common Stock Offering [Member] | |
Common stock warrants, outstanding (in shares) | shares | 33,649 |
Range of exercise price (in dollars per share) | $ 64.08 |
Note 8 - Stock-based Compensa_3
Note 8 - Stock-based Compensation (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Jan. 01, 2022 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 10.35 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value | $ 300,000 | $ 100,000 | $ 500,000 | $ 300,000 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) | 0 | ||||
Share-Based Payment Arrangement, Expense | 278,130 | 297,280 | $ 556,261 | 478,560 | |
Share-Based Payment Arrangement, Option [Member] | |||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | 1,100,000 | $ 1,100,000 | |||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year 11 months 4 days | ||||
Restricted Stock Units (RSUs) [Member] | |||||
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares) | 308 | ||||
Restricted Stock Units (RSUs) [Member] | Director [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) | 18 months | ||||
Restricted Stock [Member] | |||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | 96,000 | $ 96,000 | |||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year 8 months 8 days | ||||
Share-Based Payment Arrangement, Expense | $ 16,000 | $ 5,000 | $ 32,000 | $ 10,000 | |
Equity Incentive Plan 2015 [Member] | |||||
Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis | 4% | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) | 81,531 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | 42,461 | 42,461 |
Note 8 - Stock-based Compensa_4
Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Stock-based compensation expense | $ 278,130 | $ 297,280 | $ 556,261 | $ 478,560 |
Research and Development Expense [Member] | ||||
Stock-based compensation expense | 58,892 | 59,567 | 117,785 | 92,567 |
General and Administrative Expense [Member] | ||||
Stock-based compensation expense | $ 219,238 | $ 237,713 | $ 438,476 | $ 385,993 |
Note 8 - Stock-based Compensa_5
Note 8 - Stock-based Compensation - Stock Option Activity (Details) | 6 Months Ended |
Jun. 30, 2022 USD ($) $ / shares shares | |
Balance at January 1, 2021 (in shares) | shares | 72,454 |
Balance at January 1, 2021 (in dollars per share) | $ / shares | $ 265.85 |
Granted (in shares) | shares | 56,300 |
Granted, weighted-average exercise price (in dollars per share) | $ / shares | $ 11.40 |
Forfeited (in shares) | shares | (5,612) |
Forfeited (in dollars per share) | $ / shares | $ 188.18 |
Expired (in shares) | shares | (260) |
Expired (in dollars per share) | $ / shares | $ 1,575 |
Options outstanding, number (in shares) | shares | 122,882 |
Options outstanding, weighted-average exercise price (in dollars per share) | $ / shares | $ 149.96 |
Options outstanding, weighted-average remaining contractual life (Year) | 8 years 9 months 18 days |
Options outstanding, aggregate intrinsic value | $ | $ 0 |
Exercisable (in shares) | shares | 60,688 |
Exercisable, weighted-average exercise price (in dollars per share) | $ / shares | $ 283.73 |
Exercisable, weighted-average remaining contractual life (Year) | 8 years 1 month 6 days |
Exercisable, aggregate intrinsic value | $ | $ 0 |
Vested and expected to vest (in shares) | shares | 122,882 |
Vested and expected to vest, weighted-average exercise price (in dollars per share) | $ / shares | $ 149.96 |
Vested and expected to vest, weighted-average remaining contractual life (Year) | 8 years 9 months 18 days |
Vested and expected to vest, aggregate intrinsic value | $ | $ 0 |
Note 8 - Stock-based Compensa_6
Note 8 - Stock-based Compensation - Fair Value Assumptions (Details) - Share-Based Payment Arrangement, Option [Member] | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Expected term (Year) | 5 years 8 months 26 days | 10 years |
Minimum [Member] | ||
Risk-free interest rate | 1.90% | 1.50% |
Expected volatility | 135% | 124.50% |
Note 8 - Stock-based Compensa_7
Note 8 - Stock-based Compensation - RSU Stock-based Payment Awards (Details) - Restricted Stock Units (RSUs) [Member] | 6 Months Ended | |
Jun. 30, 2022 $ / shares shares | ||
Unvested, shares (in shares) | shares | 5,509 | |
Unvested, Weighted-average grant date fair value (in dollars per share) | $ / shares | $ 34.78 | |
Vested, shars (in shares) | shares | (837) | [1] |
Vested, Weighted-average grant date fair value (in dollars per share) | $ / shares | $ 29.87 | |
Unvested, shares (in shares) | shares | 4,672 | |
Unvested, Weighted-average grant date fair value (in dollars per share) | $ / shares | $ 35.66 | |
[1]The RSUs vested during the three months ended March 31, 2022 were settled on a hybrid basis. The Company withheld 120 shares of common stock and, in lieu of delivering such shares, paid the RSU holder an amount in cash equal to the fair market value of such shares on vesting date, representing the holder's approximate tax liability associated with such vesting amount in cash equal to the fair market value of such shares on vesting date, representing the holder's approximate tax liability associated with such vesting. |
Note 9 - Commitments and Cont_2
Note 9 - Commitments and Contingencies (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Operating Lease, Payments | $ 2,000 | $ 29,000 | $ 11,000 | $ 60,000 |
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent | 90% | |||
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay | 4% | |||
Defined Contribution Plan, Employer Discretionary Contribution Amount | $ 26,000 | $ 24,000 | $ 53,000 | $ 40,000 |